Samsung Electronics (005930.KS), the world's largest memory-chip and smartphone maker, said on June 10 that it has invested $175 million (about ₩240 billion) in the upsized Series E round of Element Biosciences, a San Diego DNA-sequencing company, and in doing so became the startup's single largest shareholder. The figures were confirmed by Korean outlets ETNews and Yonhap and by Reuters, with the round and Samsung's role detailed in Element's own announcement.
For a fund manager, the first question is not the headline number but the logic: why is a semiconductor giant anchoring a venture round in a US biotech, and what does "largest shareholder" actually buy?
The size tells you this is a strategic probe, not a capital event
The $175 million is small relative to Samsung's spending power. Yonhap reported, in a separate disclosure within the same news cycle, that Samsung Electronics spent roughly ₩90 trillion ($59.2 billion) on capital expenditure and R&D last year — the most of any chipmaker. The Element check is on the order of a quarter of one percent of that annual outlay. This is a targeted position in a growth market, not a balance-sheet-moving commitment, and it should be read as Samsung buying optionality in precision medicine rather than pivoting capital away from chips.
Element is not a new name on Samsung's books. Samsung first backed the company in its $277 million Series D round announced in July 2024, according to Element's announcement and the San Diego Business Journal. The 2026 Series E therefore deepens an existing relationship rather than opening one — the kind of follow-on that typically signals an investor is satisfied with progress. TM Roh, president of Samsung's Device eXperience (DX) Division, said in Element's release that "Element has made remarkable progress since our prior investment," adding that Samsung "continues to invest at the forefront of medtech, life sciences and precision medicine."
What Samsung is actually buying
Element, co-founded in 2017 by CEO Molly He, CTO Michael Previte and Matthew Kellinger, sells benchtop DNA sequencers — its AVITI system launched in 2022 — that compete in a market long dominated by incumbent Illumina (NASDAQ: ILMN). Element said the new financing will fund commercialization of its sequencing line, including AVITI and the recently announced VITARI, plus the forthcoming AVITI Dx and AVITI24 tissue-profiling launches. The company reports a presence in more than 40 countries across academic, pharmaceutical, biotech and clinical customers. He called the round "a powerful vote of confidence in our vision, our technology, and our team's ability to execute."
A notable gap: Element declined to disclose the total size of the Series E or the company's post-money valuation, per its announcement and Reuters. For external context only, startup tracker Tracxn pegged Element's valuation at roughly $1 billion as of February 2026 — a third-party estimate, not a figure confirmed by the company or by this round.
The open question
Becoming "largest shareholder" with an undisclosed stake percentage leaves the most important number unstated. The next concrete data points to watch are whether the launches Element is funding — AVITI Dx and AVITI24 — convert into reported revenue traction against Illumina, and whether Samsung Electronics quantifies the holding in a future filing on DART (Korea's electronic corporate disclosure system) or in its half-year report. Until then, the deal is best read as a measured extension of Samsung's medtech and life-sciences push, sized to learn rather than to bet the company.
This article is for informational purposes only and does not constitute investment advice. It reflects publicly reported information as of June 10, 2026, and readers should conduct their own research before making any financial decisions.
